These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 5569526)

  • 1. The influence of fibrin crosslinking on the kinetics of urokinase-induced clot lysis.
    McDonagh RP; McDonagh J; Duckert F
    Br J Haematol; 1971 Sep; 21(3):323-32. PubMed ID: 5569526
    [No Abstract]   [Full Text] [Related]  

  • 2. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women.
    Sidelmann JJ; Kluft C; Krug AH; Winkler U; Jespersen J; Gram JB
    Thromb Haemost; 2017 Apr; 117(4):700-705. PubMed ID: 28150855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation.
    Nielsen VG; Cohen BM; Cohen E
    Blood Coagul Fibrinolysis; 2006 Jan; 17(1):75-81. PubMed ID: 16607085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro potentiation of urokinase-activated lysis of human fibrin clots.
    Singh K; Vézina C
    J Med; 1974; 5(6):297-302. PubMed ID: 4528600
    [No Abstract]   [Full Text] [Related]  

  • 6. Urokinase-induced fibrinolysis of 125-I-fibrin. Conditions for first-order activation kinetics, density-gradient separation of split products, and a microassay.
    Ball AP; Day ED
    Thromb Diath Haemorrh; 1970 Dec; 24(3):463-74. PubMed ID: 5503943
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of factor XIIIa activity on human whole blood clot lysis in vitro.
    Jansen JW; Haverkate F; Koopman J; Nieuwenhuis HK; Kluft C; Boschman TA
    Thromb Haemost; 1987 Apr; 57(2):171-5. PubMed ID: 2440124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin.
    Camiolo SM; Thorsen S; Astrup T
    Proc Soc Exp Biol Med; 1971 Oct; 138(1):277-80. PubMed ID: 5125527
    [No Abstract]   [Full Text] [Related]  

  • 9. [Fibrinolysis: kinetics of the lysis of a fibrin clot].
    Daver J; Edmond E; Panak E; Ricoeur M
    Rev Eur Etud Clin Biol; 1970 Mar; 15(3):333-42. PubMed ID: 4246032
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasmin digestion of stabilized and non-stabilized fibrin illustrated by immunoelectrophoresis and haemagglutination inhibition immuno assays.
    Feddersen C; Gormsen J
    Scand J Haematol; 1971; 8(6):461-9. PubMed ID: 4258528
    [No Abstract]   [Full Text] [Related]  

  • 11. Fibrinolysis and coagulation. Effect of calcium and of coagulation on the lysis of fibrin clots.
    Helle I
    Scand J Haematol Suppl; 1968; 4():1-46. PubMed ID: 4181525
    [No Abstract]   [Full Text] [Related]  

  • 12. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII.
    Nielsen VG; Steenwyk BL; Gurley WQ
    J Heart Lung Transplant; 2006 Oct; 25(10):1247-52. PubMed ID: 17045938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fibrinolytic action of flufenamate and its influence on plasminogen binding to fibrin.
    Chevallet-Prandini MH; Chapel A; Suscillon M
    Thromb Res; 1985 Jun; 38(5):481-9. PubMed ID: 4012673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A method to correct for the continuing activation during the second stage in a two-stage assay. Exemplified by urokinase activation of plasminogen determined by the lysis time method.
    Berg W
    Thromb Diath Haemorrh; 1968 Mar; 19(1):161-8. PubMed ID: 4231459
    [No Abstract]   [Full Text] [Related]  

  • 15. Clot structure modification by fondaparinux and consequence on fibrinolysis: a new mechanism of antithrombotic activity.
    Varin R; Mirshahi S; Mirshahi P; Kierzek G; Sebaoun D; Mishal Z; Vannier JP; Yvonne Borg J; Simoneau G; Soria C; Soria J
    Thromb Haemost; 2007 Jan; 97(1):27-31. PubMed ID: 17200767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect and mechanism of recombinant hirudin on fibrinolysis].
    Li M; Zhang RJ; Cao GX; Wan WX; Zhang LF; Jin J
    Yao Xue Xue Bao; 2006 Sep; 41(9):814-8. PubMed ID: 17111825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinolytic agents and their effects on the haemostatic system.
    Kluft C
    Klin Wochenschr; 1988; 66 Suppl 12():50-4. PubMed ID: 2964542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model.
    Shenkman B; Livnat T; Lubetsky A; Tamarin I; Budnik I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Jul; 23(5):370-8. PubMed ID: 22498982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
    Gurewich V; Pannell R
    Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of fibrinolytic activity by measuring the lysis time of a tissue-factor-induced clot: a feasibility evaluation.
    Cellai AP; Lami D; Magi A; Liotta AA; Rogolino A; Antonucci E; Bandinelli B; Abbate R; Prisco D
    Clin Appl Thromb Hemost; 2010 Jun; 16(3):337-44. PubMed ID: 19117964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.